US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.69 against a street estimate of 0.62 — a beat of 11.3%.
Analysts rate Viatris Inc a hold (3 buy, 5 hold, 1 sell out of 9) with an average price target of $18.67.
CONFIDENT Viatris beat Q2 expectations with 3.5% revenue growth and raised full-year guidance across all metrics. China surged 16% YoY; pipeline progresses with Winland approved, selatogrel and cenerimod Phase III data expected H1 2027. Nashik fire disruptions quantified at $100–150M H2 impact. Q2 2026 China e-commerce 10–15% of business; policy implementation uncertainty on hospital procurement H2 expected, though all channels grew. Emerging markets constrained by ARV generic supply shortages. Developed markets solid on complex generics but offset by Brena/Wixela competitive pressure. Analysts pressed on China durability and policy execution uncertainty; management acknowledged provincial variability, deferred clarity to November. Selatogrel endpoint design and cenerimod belimumab co-treatment risks probed; management defended dual-study robustness. Meloxicam peak sales and value-added …
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.34% |
| Davis Selected Advisers | 6.55% |
| Vanguard Capital Management, LLC | 6.51% |
| T. Rowe Price Associates, Inc. | 5.73% |
| Vanguard Portfolio Management, LLC | 4.69% |
| State Street Corp | 4.55% |
| Rubric Capital Management LP | 2.92% |
| Geode Capital Management, LLC | 2.77% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 VIATRIS INC. - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Sales (6 months): $7,255.6 million vs. $6,812.2 million pri | 2026-08-06 |
| Results announced · Q3 2026 VIATRIS INC. — Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenues: $3.8 billion in Q2 2026, up 5% reported / 3.5% operational vs. Q2 2025 • | 2026-08-06 |
| Material agreement · Q3 2026 VIATRIS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New term loan facility: ¥40,000,000,000 (Japanese Yen) senior unsecured term loan • Interest rate | 2026-07-01 |
| Material agreement · Q2 2026 VIATRIS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Viatris completed a public offering of €650,000,000 aggregate principal amount of 4.250% Senior N | 2026-06-18 |
| Company announcement · Q2 2026 VIATRIS INC. (VTRS) – FORM 8-K SUMMARY HEADLINE NUMBERS • Debt Offering Amount: €650,000,000 (approximately $650 million USD equivalent) in Senior N | 2026-06-15 |
| Quarterly report · Q1 2026 VIATRIS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $3,509.7 million vs. $3,243.2 million in Q1 2025 (+8.2%) • Total revenues | 2026-05-07 |
| Proxy statement · Q2 2026 VIATRIS INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Scott A. Smith (CEO) total compensation for 2025: $16,752,000 (exact figure from 2025 Summar | 2026-04-02 |
| Annual report FY2025 VIATRIS INC. — 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • 2025 Total Revenues: $14.30 billion (despite divestitures and manufacturing disruptions) • | 2026-02-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.12 / share ex-date Aug 21, 2026 · pay Sep 16, 2026 | 2026-08-21 |
| Dividend | $0.12 / share ex-date May 22, 2026 · pay Jun 17, 2026 | 2026-05-22 |
| Dividend | $0.12 / share ex-date Mar 9, 2026 · pay Mar 18, 2026 | 2026-03-09 |
| Dividend | $0.12 / share ex-date Nov 24, 2025 · pay Dec 15, 2025 | 2025-11-24 |
| Dividend | $0.12 / share ex-date Aug 22, 2025 · pay Sep 15, 2025 | 2025-08-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viatris Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.